Trade

with

DARA Biosciences Inc
(NASDAQ: DARA)
AdChoices
0.9199
+0.0199
+2.21%
After Hours :
-
-
-

Open

0.9400

Previous Close

0.9000

Volume (Avg)

90.65k (634.03k)

Day's Range

0.8710-0.9400

52Wk Range

0.7852-4.40

Market Cap.

17.55M

Dividend Rate ( Yield )

-

Beta

1.50

Shares Outstanding

19.50M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 419.32k

    • Net Income

    • -9.97M

    • Market Cap.

    • 17.55M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,135.45

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.50

    • Forward P/E

    • -

    • Price/Sales

    • 7.29

    • Price/Book Value

    • 0.94

    • Price/Cash flow

    • -0.78

      • EBITDA

      • -9.86M

      • Return on Capital %

      • -66.82

      • Return on Equity %

      • -73.81

      • Return on Assets %

      • -66.82

      • Book Value/Share

      • 0.95

      • Shares Outstanding

      • 19.50M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 16.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 432.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 62.20

            • 82.75

            • Pre-Tax Margin

            • -1,162.76

            • 39.38

            • Net Profit Margin

            • -1,135.45

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 8.03

              • 2.92

              • Quick Ratio

              • 7.84

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.09

              • 2.21

              • Book Value/Share

              • 0.95

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.62

                • 277.78

                • P/E Ratio 5-Year High

                • -38.17

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.56

                • 124.82

                • Price/Sales Ratio

                • 7.05

                • 9.35

                • Price/Book Value

                • 0.91

                • 8.50

                • Price/Cash Flow Ratio

                • -0.78

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -73.81

                    (-150.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -66.82

                    (-109.60)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -73.66

                    (-148.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.46

                  • 1.48

                  • Asset Turnover

                  • 0.06

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -10.49M
                  Operating Margin
                  -2,501.50
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -0.78
                  Ownership

                  Institutional Ownership

                  7.72%

                  Top 10 Institutions

                  14.38%

                  Mutual Fund Ownership

                  0.39%

                  Float

                  99.01%

                  5% / Insider Ownership

                  9.47%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Extended Market Index Fund

                  •  

                    67,781

                  • 20.03

                  • 0.35

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    4,466

                  • 0.00

                  • 0.02

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    1,702

                  • 0.00

                  • 0.01

                  • Vanguard US Equity Index

                  •  

                    1,700

                  • 0.00

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    726,016

                  • +57.86%

                  • 3.78

                  • Vanguard Group, Inc.

                  •  

                    32,770

                  • -68.35%

                  • 0.17

                  • Nomura Holdings Inc

                  •  

                    20,520

                  • +12.61%

                  • 0.11

                  • GRT Capital Partners LLC

                  •  

                    12,799

                  • -40.74%

                  • 0.07

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  DARA Biosciences, Inc., was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acqui...moresition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox® (oral liquid tamoxifen). The Company’s main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Sol...moretamox has been approved by the U.S. Food and Drug Administration (‘FDA’) for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company’s agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman’s gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company’s advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.lessless

                  Key People

                  Christopher G. Clement

                  CEO/Director/President

                  Dr. David J. Drutz,M.D.

                  Chief Medical Officer/Director/Chairman of the Board

                  Haywood D. Cochrane,Jr

                  Vice Chairman of the Board/Director

                  David L. Tousley

                  CFO

                  Ms. Gail F. Lieberman

                  Director

                  • DARA Biosciences Inc

                  • 8601 Six Forks Road

                  • Raleigh, NC 27615

                  • USA.Map

                  • Phone: +1 919 872-5578

                  • Fax: -

                  • darabiosciences.com

                  Incorporated

                  1993

                  Employees

                  14

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: